Perettie will succeed Troy Cox. Perettie brings more than two decades of scientific and commercial experience with global biopharmaceutical organisations, most recently having served as a senior vice president in global oncology product strategy for Roche's Oncology unit.
She joins Foundation Medicine from Roche, where she's led one of the largest global oncology portfolios. Perettie has led several successful product launches in the US and abroad for Roche and Genentech across the oncology portfolio, including in breast cancer and hematology.
Perettie began her tenure at Genentech as a program team leader for bevacizumab, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma.
She has held roles of increasing responsibility at Genentech since joining in 2004, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development.
Perettie took a hiatus from Genentech in 2012 to join Sarah Cannon Research Institute as president, Global Development Innovations.
There, she was responsible for leading and growing SCRI's contract research organization business globally, driving the execution of critical oncology clinical trials during her tenure.
Before joining Genentech, Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corp.
She started her career as a senior research associate at Johns Hopkins University, before taking on a research scientist associate director role at Chiron Corp.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib